SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/53318"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/53318" > A multicenter clini...

A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery.

Olofsson, Christina (författare)
Ahl, Torbjörn (författare)
Johansson, Torsten, 1958- (författare)
Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Ortopedi och Idrottsmedicin,Ortopedkliniken Linköping
visa fler...
Larsson, Sune (författare)
Nellgård, Per, 1956 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
Ponzer, Sari (författare)
Karolinska Institutet
Fagrell, Bengt (författare)
Przybelski, Robert (författare)
Keipert, Peter (författare)
Winslow, Nancy (författare)
Winslow, Robert M (författare)
visa färre...
 (creator_code:org_t)
Ovid Technologies (Wolters Kluwer Health), 2006
2006
Engelska.
Ingår i: Anesthesiology. - : Ovid Technologies (Wolters Kluwer Health). - 0003-3022 .- 1528-1175. ; 105:6, s. 1153-63
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: Hemospan (Sangart Inc., San Diego, CA), a polyethylene glycol-modified hemoglobin with unique oxygen transport properties, has successfully completed a phase I trial in healthy volunteers. Because adverse events are expected to increase with age, the authors conducted a phase II safety study of Hemospan in elderly patients undergoing elective hip arthroplasty during spinal anesthesia. METHODS: Ninety male and female patients, American Society of Anesthesiologists physical status I-III, aged 50-89 yr, in six Swedish academic hospitals were randomly assigned to receive either 250 or 500 ml Hemospan or Ringer's acetate (30 patients/group) before induction of spinal anesthesia. Safety assessment included vital signs and Holter monitoring from infusion to 24 h, evaluation of laboratory values, and fluid balance. The hypothesis to be tested was that the incidence of adverse events would be no more frequent in patients who received Hemospan compared with standard of care (Ringer's acetate). RESULTS: Three serious adverse events were noted, none of which was deemed related to study treatment. Liver enzymes, amylase, and lipase increased transiently in patients in all three groups. There were no significant differences in electrocardiogram or Holter parameters, but there was a suggestion of more bradycardic events in the treated groups. Hypotension was less frequent in the treated patients compared with controls. CONCLUSIONS: In comparison with Ringer's acetate, Hemospan mildly elevates hepatic enzymes and lipase and is associated with less hypotension and more bradycardic events. The absence of a high frequency of serious adverse events suggests that further clinical trials should be undertaken.

Nyckelord

Aged
Aged
80 and over
Anesthesia
Spinal
Arthroplasty
Replacement
Hip
Blood Loss
Surgical
Blood Substitutes
adverse effects
therapeutic use
Blood Transfusion
Body Weight
physiology
Double-Blind Method
Electrocardiography
drug effects
Electrocardiography
Ambulatory
Enzymes
blood
Female
Hemoglobins
adverse effects
chemistry
therapeutic use
Humans
Isotonic Solutions
Male
Maleimides
adverse effects
therapeutic use
Middle Aged
Orthopedic Procedures
Polyethylene Glycols
adverse effects
therapeutic use
Water-Electrolyte Balance
physiology
MEDICINE

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy